Stem Cells (STEM) has announced the first patient to receive a high dose of one million purified human neural stem cells (HuCNS-SC®) in their Phase 1/2 clinical trial. This followed an independent review by the Data Safety Monitoring Committee, which found no safety issues with proceeding to the high dose.
The 16-patient trial is designed to evaluate the safety and efficacy of HuCNS-SC cells as a treatment for dry AMD. Subjects will be evaluated over a one-year period, with a four-year observational study to follow.
Retina Foundation of the Southwest and the Byers Eye Institute at Stanford are currently participating in the trial, with three more centers to join within the next nine months.